Recombinant Human Erythropoietin Prevents Neuropathic Pain in Rats

JIA Hong-bin,JIN Yi,LIU Jian,ZHU Si-hai,LI Wei-yan,XU Jian-guo
DOI: https://doi.org/10.3969/j.issn.1008-8199.2012.10.005
2012-01-01
Abstract:Objective Neuropathic pain is a refractory disease,and searching for new therapeutic drugs for it remains an important task for future studies of the disease.This article is to investigate the effect of intraperitoneal administration of recombinant human erythropoietin(rhEPO) before L5 spinal nerve transection(SNT) on mechanical and thermal hyperalgesia in rats.Methods We made rat models of neuropathic pain by L5 SNT and equally randomized 50 male SD rats to a sham-operation group,an L5 SNT+saline group given isotonic saline,and 3 L5 SNT+rhEPO groups treated with rhEPO at 1000,3000 and 5000 U/kg,respectively,administered intraperitoneally 1 day before surgery for consecutive 7 days.We measured the hind paw mechanical withdrawal threshold(MWT) and thermal withdrawal latency(TWL) of all the animals at 7 days after surgery using von Frey hairs and Hargreaves tests,respectively.Results Intraperitoneal administration of rhEPO at 3000 and 5000 U/kg significantly attenuated mechanical and thermal hyperalgesia of the model rats as compared with the saline controls.Conclusion Administration of rhEPO at 3000 or 5000 U/kg can prevent neuropathic pain induced by L5 spinal nerve transection.
What problem does this paper attempt to address?